Exelixis Inc
NASDAQ:EXEL
Exelixis Inc
Revenue
Exelixis Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Exelixis Inc
NASDAQ:EXEL
|
Revenue
$1.8B
|
CAGR 3-Years
23%
|
CAGR 5-Years
16%
|
CAGR 10-Years
50%
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.1B
|
CAGR 3-Years
3%
|
CAGR 5-Years
4%
|
CAGR 10-Years
9%
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$28.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
Exelixis Inc
Revenue Breakdown
Breakdown by Geography
Exelixis Inc
Total Revenue:
1.8B
USD
|
United States:
1.6B
USD
|
Europe:
145m
USD
|
Japan:
39.5m
USD
|
Breakdown by Segments
Exelixis Inc
See Also
What is Exelixis Inc's Revenue?
Revenue
1.8B
USD
Based on the financial report for Dec 29, 2023, Exelixis Inc's Revenue amounts to 1.8B USD.
What is Exelixis Inc's Revenue growth rate?
Revenue CAGR 10Y
50%
Over the last year, the Revenue growth was 14%. The average annual Revenue growth rates for Exelixis Inc have been 23% over the past three years , 16% over the past five years , and 50% over the past ten years .